Microscopic Colitis: Pathogenesis and Diagnosis

Abstract

Microscopic colitis is a type of inflammatory bowel disease and is classified as either collagenous colitis or lymphocytic colitis. The typical presentation is chronic watery diarrhea. The disease occurs more frequently in women aged 60–65 years and is increasing in incidence. The pathophysiology of microscopic colitis remains poorly understood and has not been well-described with possible several pathogeneses. To date, the diagnosis of microscopic colitis depends on histological tissue obtained during colonoscopy. Other non-invasive biomarkers, such as inflammatory markers and fecal biomarkers, have been studied in microscopic colitis, but the results remains inconclusive. The approach to chronic diarrhea is important and being able to differentiate chronic diarrhea in patients with microscopic colitis from other diseases, such as inflammatory bowel disease, functional diarrhea, and malignancy, by using non-invasive biomarkers would facilitate patient management. The management of microscopic colitis should be based on each individual’s underlying pathogenesis and involves budesonide, bile acid sequestrants, or immunosuppressive drugs in refractory cases. Cigarette smoking and certain medications, especially proton pump inhibitors, should be eliminated, when possible, after the diagnosis is made.

Effects of proton pump inhibitors on inflammatory bowel disease: An updated review

“…They revealed that PPI users have a significantly higher risk of IBD (adjusted OR = 2.43, 95%CI: 1.18-5.02). A subgroup analysis showed that collagenous colitis (CC) and lymphocytic colitis (LC) can be considered attenuated forms of IBD[ 76 ]. The significant correlations between PPI exposure and the risk of CC and LC were 4.73 (95%CI: 1.99-11.22) and 3.77 (95%CI: 2.91-4.87), respectively.…”